Vir Biotechnology Reports Positive Phase 3 Results for Chronic Hepatitis Delta Treatment

Vir Biotechnology announced positive topline results from its Phase 3 ECLIPSE 1 trial for chronic hepatitis delta (CHD). The monthly subcutaneous combination of elebsiran and tobevibart met all primary and key secondary endpoints, achieving 100% virologic response at Week 24 and 79% undetectable virus at Week 48. The treatment was well-tolerated, with a U.S. FDA regulatory filing planned for mid-2027, indicating a potential new therapy for CHD.